Phospholipase A2 Activity During the Replication Cycle of the Flavivirus West Nile Virus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Rise and Fall of the Bovine Corpus Luteum
University of Nebraska Medical Center DigitalCommons@UNMC Theses & Dissertations Graduate Studies Spring 5-6-2017 The Rise and Fall of the Bovine Corpus Luteum Heather Talbott University of Nebraska Medical Center Follow this and additional works at: https://digitalcommons.unmc.edu/etd Part of the Biochemistry Commons, Molecular Biology Commons, and the Obstetrics and Gynecology Commons Recommended Citation Talbott, Heather, "The Rise and Fall of the Bovine Corpus Luteum" (2017). Theses & Dissertations. 207. https://digitalcommons.unmc.edu/etd/207 This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It has been accepted for inclusion in Theses & Dissertations by an authorized administrator of DigitalCommons@UNMC. For more information, please contact [email protected]. THE RISE AND FALL OF THE BOVINE CORPUS LUTEUM by Heather Talbott A DISSERTATION Presented to the Faculty of the University of Nebraska Graduate College in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy Biochemistry and Molecular Biology Graduate Program Under the Supervision of Professor John S. Davis University of Nebraska Medical Center Omaha, Nebraska May, 2017 Supervisory Committee: Carol A. Casey, Ph.D. Andrea S. Cupp, Ph.D. Parmender P. Mehta, Ph.D. Justin L. Mott, Ph.D. i ACKNOWLEDGEMENTS This dissertation was supported by the Agriculture and Food Research Initiative from the USDA National Institute of Food and Agriculture (NIFA) Pre-doctoral award; University of Nebraska Medical Center Graduate Student Assistantship; University of Nebraska Medical Center Exceptional Incoming Graduate Student Award; the VA Nebraska-Western Iowa Health Care System Department of Veterans Affairs; and The Olson Center for Women’s Health, Department of Obstetrics and Gynecology, Nebraska Medical Center. -
The Role of Phospholipases A2 in Schizophrenia
Molecular Psychiatry (2006) 11, 547–556 & 2006 Nature Publishing Group All rights reserved 1359-4184/06 $30.00 www.nature.com/mp FEATURE REVIEW The role of phospholipases A2 in schizophrenia MH Law1, RGH Cotton1 and GE Berger1,2 1Genomic Disorders Research Centre, Melbourne, VI, Australia and 2ORYGEN Research Centre, Melbourne, VI, Australia A range of neurotransmitter systems have been implicated in the pathogenesis of schizophrenia based on the antidopaminergic activities of antipsychotic medications, and chemicals that can induce psychotic-like symptoms, such as ketamine or PCP. Such neurotransmitter systems often mediate their cellular response via G-protein-coupled release of arachidonic acid (AA) via the activation of phospholipases A2 (PLA2s). The interaction of three PLA2s are important for the regulation of the release of AA – phospholipase A2 Group 2 A, phospholipase A2 Group 4A and phospholipase A2 Group 6A. Gene variations of these three key enzymes have been associated with schizophrenia with conflicting results. Preclinical data suggest that the activity of these three enzymes are associated with monoaminergic neurotransmission, and may contribute to the differential efficacy of antipsychotic medications, as well as other biological changes thought to underlie schizophrenia, such as altered neurodevelopment and synaptic remodelling. We review the evidence and discuss the potential roles of these three key enzymes for schizophrenia with particular emphasis on published association studies. Molecular Psychiatry (2006) 11, 547–556. doi:10.1038/sj.mp.4001819; published online 4 April 2006 Keywords: review; schizophrenia/genetics; PLA2/genetics; arachidonic acid; common diseases; PLA2/schizophrenia Introduction (PLA2GVIA, PLA2G6A), dopamine, serotonin, G- protein-coupled receptor, eicosanoids and phospho- Neurotransmitters, such as dopamine, serotonin and lipids. -
Biopan: a Web-Based Tool to Explore Mammalian Lipidome Metabolic Pathways on LIPID MAPS[Version 1; Peer Review: 2 Approved]
F1000Research 2021, 10:4 Last updated: 29 JAN 2021 SOFTWARE TOOL ARTICLE BioPAN: a web-based tool to explore mammalian lipidome metabolic pathways on LIPID MAPS [version 1; peer review: 2 approved] Caroline Gaud 1, Bebiana C. Sousa 2, An Nguyen1, Maria Fedorova3, Zhixu Ni 3, Valerie B. O’Donnell4, Michael J.O. Wakelam2+, Simon Andrews1, Andrea F. Lopez-Clavijo 2 1Bioinformatics Group, Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK 2Lipidomics facility, Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, UK 3Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Center for Biotechnology and Biomedicine, Universität Leipzig, Leipzig, 04109, Germany 4Systems Immunity Research Institute, School of Medicine, Cardiff University, Cardiff, CF14 4XN, UK + Deceased author v1 First published: 06 Jan 2021, 10:4 Open Peer Review https://doi.org/10.12688/f1000research.28022.1 Latest published: 06 Jan 2021, 10:4 https://doi.org/10.12688/f1000research.28022.1 Reviewer Status Invited Reviewers Abstract Lipidomics increasingly describes the quantitation using mass 1 2 spectrometry of all lipids present in a biological sample. As the power of lipidomics protocols increase, thousands of lipid molecular species version 1 from multiple categories can now be profiled in a single experiment. 06 Jan 2021 report report Observed changes due to biological differences often encompass large numbers of structurally-related lipids, with these being 1. Amaury Cazenave Gassiot , Yong Loo Lin regulated by enzymes from well-known metabolic pathways. As lipidomics datasets increase in complexity, the interpretation of their School of Medicine, Singapore, Singapore results becomes more challenging. BioPAN addresses this by 2. -
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z
REVIEW pubs.acs.org/CR The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease Jonathan Z. Long* and Benjamin F. Cravatt* The Skaggs Institute for Chemical Biology and Department of Chemical Physiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States CONTENTS 2.4. Other Phospholipases 6034 1. Introduction 6023 2.4.1. LIPG (Endothelial Lipase) 6034 2. Small-Molecule Hydrolases 6023 2.4.2. PLA1A (Phosphatidylserine-Specific 2.1. Intracellular Neutral Lipases 6023 PLA1) 6035 2.1.1. LIPE (Hormone-Sensitive Lipase) 6024 2.4.3. LIPH and LIPI (Phosphatidic Acid-Specific 2.1.2. PNPLA2 (Adipose Triglyceride Lipase) 6024 PLA1R and β) 6035 2.1.3. MGLL (Monoacylglycerol Lipase) 6025 2.4.4. PLB1 (Phospholipase B) 6035 2.1.4. DAGLA and DAGLB (Diacylglycerol Lipase 2.4.5. DDHD1 and DDHD2 (DDHD Domain R and β) 6026 Containing 1 and 2) 6035 2.1.5. CES3 (Carboxylesterase 3) 6026 2.4.6. ABHD4 (Alpha/Beta Hydrolase Domain 2.1.6. AADACL1 (Arylacetamide Deacetylase-like 1) 6026 Containing 4) 6036 2.1.7. ABHD6 (Alpha/Beta Hydrolase Domain 2.5. Small-Molecule Amidases 6036 Containing 6) 6027 2.5.1. FAAH and FAAH2 (Fatty Acid Amide 2.1.8. ABHD12 (Alpha/Beta Hydrolase Domain Hydrolase and FAAH2) 6036 Containing 12) 6027 2.5.2. AFMID (Arylformamidase) 6037 2.2. Extracellular Neutral Lipases 6027 2.6. Acyl-CoA Hydrolases 6037 2.2.1. PNLIP (Pancreatic Lipase) 6028 2.6.1. FASN (Fatty Acid Synthase) 6037 2.2.2. PNLIPRP1 and PNLIPR2 (Pancreatic 2.6.2. -
Phosphoproteomics Identify Arachidonic-Acid-Regulated Signal Transduction Pathways Modulating Macrophage Functions with Implications for Ovarian Cancer
Phosphoproteomics identify arachidonic-acid-regulated signal transduction pathways modulating macrophage functions with implications for ovarian cancer Raimund Dietze1¶, Mohamad K. Hammoud1¶, María Gómez-Serrano1, Annika Unger1, Tim Bieringer1§, Florian Finkernagel1, Anna M. Sokol2,3, Andrea Nist4, Thorsten Stiewe4, Silke Reinartz1, Viviane Ponath5, Christian Preußer5, Elke Pogge von Strandmann5, Sabine Müller- Brüsselbach1, Johannes Graumann2,3 and Rolf Müller1* 1Tranlational OncologY Group, Center for Tumor BiologY and Immunology, Philipps University, Marburg, GermanY 2Biomolecular Mass Spectrometry, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, GermanY 3The German Centre for Cardiovascular Research (DZHK), Partner Site Rhine-Main, Max Planck Institute for Heart and Lung Research, Bad Nauheim, GermanY 4Genomics Core Facility, Philipps UniversitY, Marburg, GermanY 5Institute for Tumor Immunology, Philipps University, Marburg, GermanY §Present address: Hochschule Landshut, 84036 Landshut, GermanY ¶Equal contribution *Corresponding author: Rolf Müller, Center for Tumor Biology and Immunology (ZTI), Philipps University, Hans-Meerwein-Strasse 3, 35043 Marburg, GermanY. Email: [email protected]. Phone: +49 6421 2866236. Running title: Signaling pathways of arachidonic acid in macrophages 1 Abstract Arachidonic acid (AA) is a polYunsaturated fatty acid present at high concentrations in the ovarian cancer (OC) microenvironment and associated with a poor clinical outcome. In the present studY, we have unraveled a potential link between AA and macrophage functions. Methods: AA-triggered signal transduction was studied in primary monocyte-derived macrophages (MDMs) by phosphoproteomics, transcriptional profiling, measurement of intracellular Ca2+ accumulation and reactive oxygen species production in conjunction with bioinformatic analyses. Functional effects were investigated by actin filament staining, quantification of macropinocytosis and analysis of extracellular vesicle release. -
Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators S
Supplemental material to this article can be found at: http://jpet.aspetjournals.org/content/suppl/2018/10/10/jpet.118.252296.DC1 1521-0103/367/3/494–508$35.00 https://doi.org/10.1124/jpet.118.252296 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 367:494–508, December 2018 Copyright ª 2018 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators s Jason R. Clapper, Cassandra L. Henry, Micah J. Niphakis, Anna M. Knize, Aundrea R. Coppola, Gabriel M. Simon, Nhi Ngo, Rachel A. Herbst, Dylan M. Herbst, Alex W. Reed, Justin S. Cisar, Olivia D. Weber, Andreu Viader, Jessica P. Alexander, Mark L. Cunningham, Todd K. Jones, Iain P. Fraser, Cheryl A. Grice, R. Alan B. Ezekowitz, ’ Gary P. O Neill, and Jacqueline L. Blankman Downloaded from Abide Therapeutics, San Diego, California Received July 26, 2018; accepted October 5, 2018 ABSTRACT Monoacylglycerol lipase (MGLL) is the primary degradative whether selective MGLL inhibition would affect prostanoid pro- jpet.aspetjournals.org enzyme for the endocannabinoid 2-arachidonoylglycerol (2- duction in several human assays known to be sensitive AG). The first MGLL inhibitors have recently entered clinical to cyclooxygenase inhibitors. ABD-1970 robustly elevated brain development for the treatment of neurologic disorders. To 2-AG content and displayed antinociceptive and antipru- support this clinical path, we report the pharmacological ritic activity in a battery of rodent models (ED50 values of characterization of the highly potent and selective MGLL inhibitor 1–2 mg/kg). -
Targeting Myelin Lipid Metabolism As a Potential Therapeutic Strategy in a Model of CMT1A Neuropathy
ARTICLE DOI: 10.1038/s41467-018-05420-0 OPEN Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy R. Fledrich 1,2,3, T. Abdelaal 1,4,5, L. Rasch1,4, V. Bansal6, V. Schütza1,3, B. Brügger7, C. Lüchtenborg7, T. Prukop1,4,8, J. Stenzel1,4, R.U. Rahman6, D. Hermes 1,4, D. Ewers 1,4, W. Möbius 1,9, T. Ruhwedel1, I. Katona 10, J. Weis10, D. Klein11, R. Martini11, W. Brück12, W.C. Müller3, S. Bonn 6,13, I. Bechmann2, K.A. Nave1, R.M. Stassart 1,3,12 & M.W. Sereda1,4 1234567890():,; In patients with Charcot–Marie–Tooth disease 1A (CMT1A), peripheral nerves display aberrant myelination during postnatal development, followed by slowly progressive demye- lination and axonal loss during adult life. Here, we show that myelinating Schwann cells in a rat model of CMT1A exhibit a developmental defect that includes reduced transcription of genes required for myelin lipid biosynthesis. Consequently, lipid incorporation into myelin is reduced, leading to an overall distorted stoichiometry of myelin proteins and lipids with ultrastructural changes of the myelin sheath. Substitution of phosphatidylcholine and phosphatidylethanolamine in the diet is sufficient to overcome the myelination deficit of affected Schwann cells in vivo. This treatment rescues the number of myelinated axons in the peripheral nerves of the CMT rats and leads to a marked amelioration of neuropathic symptoms. We propose that lipid supplementation is an easily translatable potential therapeutic approach in CMT1A and possibly other dysmyelinating neuropathies. 1 Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Göttingen 37075, Germany. -
Cytoplasmic Labile Iron Accumulates in Aging Stem Cells Perturbing a Key Rheostat for Identity Control
bioRxiv preprint doi: https://doi.org/10.1101/2021.08.03.454947; this version posted August 5, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cytoplasmic labile iron accumulates in aging stem cells perturbing a key rheostat for identity control Yun-Ruei Kao1,#,*, Jiahao Chen2,#, Rajni Kumari2, Madhuri Tatiparthy2, Yuhong Ma2,§, Maria M. Aivalioti2,§, Aliona Zintiridou2, Victor Thiruthuvanathan2, Julie A. Reisz3, Stephanie Stranski4, Simone Sidoli4, Ulrich Steidl1,2,5,6, Angelo D’Alessandro3, Britta Will1,2,5,6,7* 1Department of Medicine, Albert Einstein College of Medicine, New York, NY, USA; 2Department of Cell Biology, Albert Einstein College of Medicine, New York, NY, USA; 3Department of Biochemistry and Molecular Genetics, University of Colorado Denver – Anschutz Medical Campus, Denver, CO, USA; 4Department of Biochemistry, Albert Einstein College of Medicine, New York, NY, USA; 5Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, New York, NY, USA; 6Blood Cancer Institute, Albert Einstein Cancer Center, Albert Einstein College of Medicine, New York, NY, USA; 7Institute for Aging Studies, Albert Einstein College of Medicine, New York, NY, USA. #,§ These authors contributed equally. Keywords: Adult stem cells; ageing; iron homeostasis; lipid metabolism; histone acetylation; gene regulation. * Corresponding authors: Britta Will, PhD Yun-Ruei Kao, PhD Albert Einstein College of Medicine Albert Einstein College of Medicine 1300 Morris Park Avenue 1300 Morris Park Avenue New York, NY 10461, USA New York, NY 10461, USA Phone: +1 718 430 3786 Phone: +1 718 430 6431 Email: [email protected] Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.08.03.454947; this version posted August 5, 2021. -
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of C-JUN–WEE1 Signaling Jie Li1,2, Chaoyun Pan1, Austin C
Published OnlineFirst April 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3790 CLINICAL CANCER RESEARCH | TRANSLATIONAL CANCER MECHANISMS AND THERAPY DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling Jie Li1,2, Chaoyun Pan1, Austin C. Boese1, JiHoon Kang1, Anna D. Umano1, Kelly R. Magliocca3, Wenqing Yang2,4, Yu Zhang2,4, Sagar Lonial1, Lingtao Jin5, and Sumin Kang1 ABSTRACT ◥ Purpose: Although platinum compounds are the first-line Results: We found that platinum resistance was mediated by treatment for ovarian cancer, the majority of patients relapse DGKA and its product, phosphatidic acid (PA), in ovarian cancer. and develop resistance to treatment. However, the mechanism Proteomic and genomic screens revealed that DGKA activates the underlying resistance is unclear. The goal of our study is to transcription factor c-JUN and consequently enhances expression decipher the mechanism by which a metabolic kinase, diacylgly- of a cell-cycle regulator, WEE1. Mechanistically, PA facilitates cerol kinase alpha (DGKA), confers platinum resistance in c-JUN N-terminal kinase recruitment to c-JUN and its nuclear ovarian cancer. localization, leading to c-JUN activation upon cisplatin exposure. Experimental Design: Metabolic kinase RNAi synthetic lethal Pharmacologic inhibition of DGKA sensitized ovarian cancer cells screening was used to identify a cisplatin resistance driver in to cisplatin treatment and DGKA–c-JUN–WEE1 signaling pos- ovarian cancer. DGKA variants were used to demonstrate the need itively correlated with platinum resistance in tumors derived from for DGKA activity in cisplatin resistance. Phospho-proteomic and patients with ovarian cancer. genomic screens were performed to identify downstream effectors Conclusions: Our study demonstrates how the DGKA-derived of DGKA. -
MAPK Signaling Determines Lysophosphatidic Acid (LPA)-Induced Inflammation in Microglia Ioanna Plastira1, Eva Bernhart1, Lisha Joshi1, Chintan N
Plastira et al. Journal of Neuroinflammation (2020) 17:127 https://doi.org/10.1186/s12974-020-01809-1 RESEARCH Open Access MAPK signaling determines lysophosphatidic acid (LPA)-induced inflammation in microglia Ioanna Plastira1, Eva Bernhart1, Lisha Joshi1, Chintan N. Koyani1,2, Heimo Strohmaier3, Helga Reicher1, Ernst Malle1 and Wolfgang Sattler1,4* Abstract Background: In the extracellular environment, lysophosphatidic acid (LPA) species are generated via autotaxin (ATX)-mediated hydrolysis of lysophospholipid precursors. Members of the LPA family are potent lipid mediators transmitting signals via six different G protein-coupled LPA receptors (LPAR1-6). The LPA signaling axis is indispensable for brain development and function of the nervous system; however, during damage of the central nervous system, LPA levels can increase and aberrant signaling events counteract brain function. Here, we investigated regulation of the ATX/LPA/LPAR axis in response to lipopolysaccharide-induced systemic inflammation in mice and potential neurotoxic polarization programs in LPA-activated primary murine microglia. Methods: In vivo, LPAR1-6 expression was established by qPCR in whole murine brain homogenates and in FACS- sorted microglia. ELISAs were used to quantitate LPA concentrations in the brain and cyto-/chemokine secretion from primary microglia in vitro. Transcription factor phosphorylation was analyzed by immunoblotting, and plasma membrane markers were analyzed by flow cytometry. We used MAPK inhibitors to study signal integration by the JNK, p38, and ERK1/2 branches in response to LPA-mediated activation of primary microglia. Results: Under acute and chronic inflammatory conditions, we observed a significant increase in LPA concentrations and differential regulation of LPAR, ATX (encoded by ENPP2), and cytosolic phospholipase A2 (encoded by PLA2G4A) gene expression in the brain and FACS-sorted microglia. -
1 Novel Expression Signatures Identified by Transcriptional Analysis
ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009. -
Differences in Metabolomic and Transcriptomic Profiles Between
Genes Nutr (2013) 8:411–423 DOI 10.1007/s12263-012-0328-0 RESEARCH PAPER Differences in metabolomic and transcriptomic profiles between responders and non-responders to an n-3 polyunsaturated fatty acids (PUFAs) supplementation Iwona Rudkowska • Ann-Marie Paradis • Elisabeth Thifault • Pierre Julien • Olivier Barbier • Patrick Couture • Simone Lemieux • Marie-Claude Vohl Received: 9 July 2012 / Accepted: 27 November 2012 / Published online: 19 December 2012 Ó Springer-Verlag Berlin Heidelberg 2012 Abstract Studies have demonstrated large within-popu- key genes in lipid metabolism: fatty acid desaturase 2, lation heterogeneity in plasma triacylglycerol (TG) phospholipase A2 group IVA, arachidonate 15-lipoxyge- response to n-3 PUFA supplementation. The objective of nase, phosphatidylethanolamine N-methyltransferase, the study was to compare metabolomic and transcriptomic monoglyceride lipase, and glycerol-3-phosphate acyl- profiles of responders and non-responders of an n-3 PUFA transferase, were expressed in opposing direction between supplementation. Thirty subjects completed a 2-week run- subgroups. In sum, results highlight key differences in lipid in period followed by a 6-week supplementation with n-3 metabolism of non-responders compared to responders PUFA (3 g/d). Six subjects did not lower their plasma TG after an n-3 PUFA supplementation, which may explain the (?9 %) levels (non-responders) and were matched to 6 inter-individual variability in plasma TG response. subjects who lowered TG (-41 %) concentrations (responders) after the n-3 PUFA supplementation. Pre-n-3 Keywords Lipidomics Á Metabolic pathways Á PUFA supplementation characteristics did not differ Metabolites Á Microarray Á Nutrigenomics between the non-responders and responders except for plasma glucose concentrations.